SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 279 participants.

Also called NCT05831202

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 279 participants (planned count) (from the registry)
Sponsor
Galaxy Therapeutics INC (from the registry)
Registry
  • NCT NCT05831202
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05831202. Allocation not applicable; no masking; primary purpose treatment. Start 2024-08-06 (actual); primary completion 2026-09-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial
Acronym
SEAL™IT
Condition
Intracranial Aneurysm
Intervention (Device)
The SEAL™ Saccular Endovascular Aneurysm Lattice System
Lead sponsor
Galaxy Therapeutics INC (class: industry)

Record details

Record id
cardio:ct-nct05831202
Content hash
91ed01578b5d387b4b9f0d41589aa6b6be2f681a7192a2b832bcec750ef8e4b5